Insulet Corp. (PODD) Retained Earnings
The retained earnings for Insulet Corp. (PODD) is $287.40 Million with a year-over-year change of +613.15%. Retained earnings represent the cumulative net income that has been kept by the company rather than distributed to shareholders as dividends. It's a key component of shareholders' equity.
PODD Retained Earnings Chart
Reported annual fiscal-period values; no daily interpolation.
Current Retained Earnings
$287.40M
$287.40 Million
Year-over-Year Change
+613.15%
vs. $40.30M prior year
Historical Data
24
Years of data available
Annual Retained Earnings History
| Year | Retained Earnings | YoY Change | % Change |
|---|---|---|---|
| 2025 | $287.40M | +$247.10M | +613.15% |
| 2024 | $40.30M | +$418.30M | +110.66% |
| 2023 | $-378.00M | +$206.30M | +35.31% |
| 2022 | $-584.30M | +$65.20M | +10.04% |
| 2021 | $-649.50M | +$16.80M | +2.52% |
| 2020 | $-666.30M | +$5.70M | +0.85% |
| 2019 | $-672.00M | +$11.61M | +1.70% |
| 2018 | $-683.61M | +$23.64M | +3.34% |
| 2017 | $-707.25M | $-26.83M | -3.94% |
| 2016 | $-680.42M | $-28.88M | -4.43% |
| 2015 | $-651.54M | $-73.52M | -12.72% |
| 2014 | $-578.02M | $-51.50M | -9.78% |
| 2013 | $-526.52M | $-44.97M | -9.34% |
| 2012 | $-481.55M | $-40.53M | -9.19% |
| 2011 | $-441.02M | $-57.17M | -14.89% |
| 2010 | $-383.85M | $-53.96M | -16.36% |
| 2009 | $-329.89M | $-81.52M | -32.82% |
| 2008 | $-248.37M | $-92.79M | -59.64% |
| 2007 | $-155.58M | $-53.54M | -52.47% |
| 2006 | $-102.04M | $-35.98M | -54.47% |
| 2005 | $-66.06M | $-21.64M | -48.71% |
| 2004 | $-44.42M | $-44.42M | — |
| 2003 | $0 | +$0 | — |
| 2002 | $0 | — | — |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy